NasdaqGM:TRDABiotechs
Entrada Therapeutics (TRDA) Quarterly Revenue Slump Tests Bullish Growth Narratives
Entrada Therapeutics (TRDA) closed out FY 2025 with Q4 revenue of US$1.3 million and a basic EPS loss of US$0.94, while trailing twelve month figures showed revenue of US$25.4 million and a basic EPS loss of US$3.47. Over the past few quarters, the company has seen quarterly revenue move from US$37.4 million in Q4 2024 to US$20.6 million in Q1 2025, then to US$1.9 million, US$1.6 million and US$1.3 million in Q2, Q3 and Q4 2025. Basic EPS shifted from a profit of US$0.03 in Q4 2024 to losses...